Dendrimers as anti-inflammatory agents by Avti, Pramod K. & Kakkar, Ashok
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 49, special issue, 2013
Ashok Kakkar is an Associate Professor 
in the Department of Chemistry at McGill 
University, Montreal, Quebec, Canada. 
His research interests include developing 
methodologies to complex architectures 
(hyperbranched macromolecules 
inc lud ing  dendr imers ,  m ik toarm 
polymers, metal nanoparticles), and 
studying their efficacy in biological 
processes including drug delivery and 
theranostics.
Pramod Avti is a Postdoctoral Fellow 
at Montreal Heart Institute, Montreal, 
Q u e b e c ,  C a n a d a  w o r k i n g  o n  a 
collaborative project with Department 
of Chemistry, McGill University and 
Ecole Polytechnique, Montreal Canada. 
His current scientific interests include 
multifunctional nanomaterials synthesis, 
and their biomedical applications. In 
particular, his research is aimed at 
synthesis, interaction and conjugation 
of drug or gene-dendrimer conjugates to the gold nanoshells for 
biomedical imaging and as theranostic agents.
*Correspondence: Ashok Kakkar. Department of Chemistry, 
801 Sherbrooke St. West, McGill University, Montreal, QC 
H3A 0B8, Canada. E- mail: ashok.kakkar@mcgill.ca
Dendrimers as anti-inflammatory agents
Pramod K. Avti1,2,3, Ashok Kakkar3,*
1Montreal Heart Institute, Research Center, Montréal, Canada, 2Institute of 
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Dendrimers constitute an intriguing class of macromolecules which find applications in 
a variety of areas including biology. These hyperbranched macromolecules with tailored 
backbone and surface groups have been extensively investigated as nanocarriers for gene 
and drug delivery, by molecular encapsulation or covalent conjugation. Dendrimers have 
provided an excellent platform to develop multivalent and multifunctional nanoconjugates 
incorporating a variety of functional groups including drugs which are known to be anti-
inflammatory agents. Recently, dendrimers have been shown to possess anti-inflammatory 
properties themselves. This unexpected and intriguing discovery has provided an additional 
impetus in designing novel active pharmaceutical agents. In this review, we highlight some 
of the recent developments in the field of dendrimers as nanoscale anti-inflammatory agents.
Uniterms: Dendrimers. Nanocarriers. Anti-inflammatory agents. Cyclooxygenase 
(COX-2). Inducible nitric oxide synthase (iNOS). Pro-inflammatory cytokines.
Dendrímeros constituem uma classe intrigante de macromoléculas que apresentam 
aplicações em diversas áreas incluindo biologia. Essas macromoléculas extremamente 
ramificadas com esqueleto planejado e grupos de superfície foram extensivamente 
investigadas como nanotransportadores de genes e de fármacos, por encapsulamento 
molecular ou conjugação covalente. Dendrímeros têm proporcionado uma plataforma 
excelente de desenvolvimento nanoconjugados multivalentes e multifuncionais 
incorporando uma variedade de grupos funcionais, incluindo fármacos que são conhecidos 
por atuarem agentes antiinflamatórios. Recentemente, os dendrímeros mostraram 
propriedades antiinflamatórias. Esta inesperada e intrigante descoberta tem proporcionado 
um impulso adicional no planejamento de novos agente farmacêuticos ativos. Nesta revisão, 
nós destacamos alguns dos desenvolvimentos recentes no campo dos dendrímeros como 
agentes antiinflamatórios em nanoescala.
Unitermos: Dendrímeros. Nanotransportadores. Agentes antiinflamatórios. Ciclooxigenase 
(COX-2). Óxido nítrico sintase induzível (iNOS). Citocinas pró-inflamatórias.
INTRODUCTION
The term dendrimer is derived from a Greek word dendron which 
means tree, and reflects their structure. Though this terminology was coined 
in the mid 1980’s by Tomalia, the first synthesis of dendrimers is credited 
to Vogtle and co-workers in 1978 (Buhleier et al., 1978). Dendrimers are 
synthetic macromolecules with well-defined shapes, and possess three 
main components: central core, repeating branch units and the dense shell 
with terminal functional groups. These distinct macromolecules depict 
unique physicochemical properties that are different than traditional linear 
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and branched polymers. This is due to the step-by-step 
controlled growth, in contrast to direct polymerization in 
well studied linear polymers, and employs small organic 
molecules as structural components to obtain monodis-
persity (Tomalia et al., 1990; Frechet, Tomalia, 2002; 
Svenson, Tomalia, 2005; Tomalia, 2005). The overall size, 
shape, molecular weight, density, polarity, flexibility and 
solubility of dendrimers are well controlled and depend on 
the choice of the structural components, central core, the 
branching units and the terminal functional groups used. 
Unlike other polymeric structures (Hadjichristidis, 2000; 
Schluter, Rabe, 2000; Hult, 2003; Haag, Kratz, 2006), 
dendrimers are easy to reproduce structurally. This has 
led to tremendous potential in their applications as drug 
delivery agents. Dendrimers can render water solubility, 
bioavailability and biocompatibility to active pharmaceuti-
cal agents. Over the years dendrimers have been developed 
based on their multivalent structure and supramolecular 
properties as attractive nanocarriers for applications in 
pharmaceutical and biomedical sciences (Sharma et al., 
2011a,b). It is no surprise then that much attention has 
been directed towards their ability as nanocontainers for 
a variety of drug molecules including anti-inflammatory 
agents (Milhem et al., 2000; Kolhe et al., 2003; Chau-
han et al., 2004; Sharma et al., 2011a; Soliman et al., 
2011). Milhem and Kolhe groups have shown that a G4 
PAMAM dendrimer can contain approximately 41 and 78 
ibuprofen (a non-steroidal anti-inflammatory drug) mol-
ecules, either by way of encapsulation into the interior 
cavities by hydrophobic interactions or attached to the 
surface by electrostatic interactions (Milhem et al., 2000; 
Kolhe et al., 2003). Chauhan and his colleagues have 
shown the encapsulation of indomethacin into PAMAM 
dendrimers to improve the in vivo distribution by ~2.3 
times at the inflamed regions as compared to the free 
drug (Chauhan et al., 2004). Other groups have reported 
the effect of dendrimer concentration, generation and 
pH effects on the solubilization of drugs (Wiwattanapa-
tapee et al., 1999; Cheng et al., 2005). These studies 
have shown that increasing the generation number of the 
dendrimer at higher pH increases drug solubility, and the 
presence of amine terminal groups would improve the 
electrostatic interactions of the drug with carboxyl end 
groups. More recently there have been reports suggesting 
that dendrimers themselves can act as anti-inflammatory 
agents. In this review, progress towards an evaluation of 
the anti-inflammatory properties of the dendrimers, are 
discussed.
Synthesis of dendrimers
The two commonly used synthetic strategies 
for dendrimers include divergent and the convergent 
methods (Buhleier et al., 1978; Tomalia et al., 1984; 
Newkome et al., 1985; Tomalia et al., 1985; Hawker, 
Frechet, 1990; Hourani, Kakkar, 2010). The divergent 
method uses bottom-up approach where the synthesis 
of dendrimer is carried out beginning at the central core 
and moves towards the surface (Figure 1). The branched 
building units react with the core, and subsequently 
their terminal groups are activated which in turn react 
with the other branched building units. The purifica-
tion process at each reaction step helps obtain uniform 
structure and specific molecular weight. The repetition 
of these reaction cycles, called as generations (G), grows 
the macromolecule outwards. The molecular weight and 
number of terminal groups are determined by the den-
drimer generation. The number of terminal groups (Z) 
could be calculated using a mathematical equation Z = 
NcNbG where Nc, Nb, G are the core multiplicity, branch 
cell multiplicity and generation number respectively 
(Frechet, Tomalia, 2001; Tomalia, 2005). Some of the 
commercially available dendrimers like polyamidoamine 
(PAMAM), polypropyleneimine (PPI) are prepared by 
the divergent synthetic method.
The convergent method developed by Frechet, uses 
top-down approach in which the synthesis starts from the 
periphery and ends towards the central core (Freeman 
et al., 1997). In this method, a branched dendron is first 
prepared, and then reacted with the central core to form 
the final dendrimer (Figure 1). The synthesis of poly(aryl 
ether) dendrimers is one common example of this method 
(Grayson, Frechet, 2001). The advantages of convergent 
methodology include easy purification of the desired 
product, defect minimized final product, easy and precise 
placement of peripheral functional groups.
FIGURE 1 - Schematic showing the divergent versus convergent synthetic strategies.
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Conformational changes
Low generation dendrimers (0, 1 and 2) possess 
asymmetric shape and open structure and become globu-
lar as higher generations are achieved. As the dendrimer 
grows, it becomes densely packed and extends out to the 
periphery, and due to steric hindrance further elongation 
or branching stops (Fischer, Vogtle, 1999). With increase 
in each generation, the branch density increases leading 
to the formation of internal cavities and a large number of 
terminal end groups.
Physicochemical properties
Some of the important physicochemical properties 
of dendrimers originate from their overall conformation, 
and their cascade architecture provides unique properties 
for applications in the biomedical field. Dendrimers in so-
lution possess rheological properties as they form closely 
packed ball like structures. The terminal end groups of the 
dendrimers render them high solubility, miscibility and 
high reactivity (Frechet, 1994).
Dendrimers as anti-inflammatory agents
In this section, we summarize not only the anti-
inflammatory role of dendrimers displayed towards 
immune cells derived from myeloid lineage (such as 
monocyte-derived macrophages (MDMs), and immature 
dendritic cells) (Shaunak et al., 2004), peripheral blood 
monocytes (Fruchon et al., 2009) and peritoneal mac-
rophages (Chauhan et al., 2009), but also towards the 
extravasation of inflammatory effectors (leukocytes) at 
the site of inflammation (Ulbrich et al., 2003), anti-HIV 
activity, anti-arthritis effect and inhibition of iNOS and 
COX-2 enzymes etc.
Proinflammatory cytokines
Recently, dendrimers without any drug encapsulated 
or covalently bound have shown therapeutic potential 
as anti-inflammatory agents. This is mainly due to the 
immunomodulatory alterations in pathophysiological re-
sponse of the immune system. The first ever report on the 
anti-inflammatory properties of dendrimers was studied as 
a preventive agent in scar tissue formation. Here, 1,2-di-
aminoethane-cored generation 4.5 poly(amidoamine) 
(PAMAM) skeleton with 64 carboxylic acid surface 
groups was used. Of the 64 carboxylic groups, nine had 
been amido-conjugated to glucosamine and glucosamine-
6-sulfate (Shaunak et al., 2004). The dendrimer glucos-
amine inhibited the release of proinflammatory chemo-
kines (macrophage inhibitory protein [MIP]-1α and -1β, 
interleukin [IL]-8) and cytokines (tumor necrosis factor 
[TNF]-α, IL-1β and IL-6) in the the lipopolysaccharide 
(LPS)-stimulated immune cells such as monocyte-derived 
macrophages (MDMs) and immature monocyte-derived 
dendritic cells (DCs) (Shaunak et al., 2004). On the 
other hand, dendrimer with nine 6-O-sulfated glucosamine 
residues (DGS) showed no inflammatory effect, but rather 
displayed anti-angiogenic properties.
Immune cellular response
PAMAM dendrimers are the most commonly stud-
ied for anti-inflammatory properties. In a recent study, 
PAMAM dendrimers with terminal-NH2 (G4-NH2), 
-OH (G4-OH) and –COOH (G4.5-CO2H) (Chauhan et al., 
2009) were used for the in vitro analysis of LPS-induced 
nitric oxide (NO) and cyclo-oxygenase 2 (COX-2) acti-
vity in rat peritoneal macrophages. G4-NH2 and G4-OH 
dendrimers showed maximum inhibitory activity as 
compared to G4.5-CO2H. In another study, the aminoeth-
ylethanolamine-capped dendrimers (G4-AEEA) and hy-
droxyl terminated dendrimers (G4-OH) displayed highest 
inhibitory activity of COX-2. Other dendrimers terminated 
with tris(hydroxymethyl)aminomethane (G4-Tris), N-(3-
carbomethoxy) pyrrolidone (G4-Pyr), or polyethylene 
glycol (G4-PEG) groups showed decreasing inhibitory 
effects. Carboxylated and succinamic acid –capped (G4-
CO2H and G4-SUC) dendrimers had no effect on COX-2 
inhibition.
Recent studies have shown that azabisphosphonate 
(capped by amino-bisphosphonate groups) (ABP) den-
drimers treatment changes the human monocytes (Vγ9Vδ2 
T lymphocytes) phenotype with an increase in their phago-
cytic activity (Espinosa et al., 2001; Poupot et al., 2006). 
ABPs have also shown to have immunomodulatory effects 
and promote natural killer (NK) cells proliferation in cul-
tures of peripheral blood mononuclear cells (PBMCs). The 
NK cells act as cytotoxic effectors against virus, bacteria 
or parasite-infected cells and also inhibit the proliferation 
of CD4+ T lymphocytes (Griffe et al., 2007; Portvein et 
al., 2009). ABPs at the gene and protein levels have shown 
increased expression of anti-inflammatory products like 
mannose receptor MRC1 with reduced levels of CD64 
and CD13 (Fruchon et al., 2009). Therefore, it is clear 
that ABP has anti-inflammatory and immunomodulatory 
effects in vitro either directly on monocytes or indirectly 
on other immune cells, and has shown some similarities 
with the glucocorticoid properties as immunosuppressive 
drugs (Ehrchen et al., 2007).
Cell adhesion molecules
Recently, Rele’s group synthesized 3- and 4-arm 
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PEO ‘stars’ and second generation dendrimer on the N3P3 
core, which showed comparable anti-inflammatory prop-
erties to that of heparin (sulfated polysaccharide) (Rele 
et al., 2005). These dendrimers have terminal hydroxyl-
ated lactose end groups in which the hydroxyls groups 
are free, acetylated or sulfated. They exhibited anti-in-
flammatory properties by blocking P-and L-selectins via 
sulfate-dependent interactions. When the PEO stars and 
sulfated PEOs were injected (20 mg/kg b.wt) into mice 
models of acute inflammation, generated by intraperi-
toneal injection of thioglycollate, it drastically reduced 
the infiltration of neutrophils and macrophages. It was 
concluded that this inhibition is brought about by the 
selectins. This was confirmed in vitro, where dendrimer 
inhibited the U937 lymphoma cell adhesion to immobi-
lized P- and L-selection without any effect on E-selectin 
similar to that of heparin. It is because of the absence 
of positively charged motifs in the binding pockets of 
E-selectin as compared to P- and L-selectin. Similarly, 
Dernedde and his colleagues synthesized polyglycerol 
sulfates (dPGS) as heparin analogs with different core 
size (2.5 and 6 kDa) and degree of sulfation (0 – 61 [dPG 
– dPGS61]) (Dernedde et al., 2010). dPGS61 showed high 
anti-inflammatory properties in the acute allergic contact 
dermatitis mice model (ear swelling, redness, edema and 
cellular infiltration) by targeting both L-selectin on leu-
kocytes and P-selectin on endothelial cells and inhibiting 
the generation of anaphylatoxin C5a (causes enhanced 
vascular permeabilization).
Anti-viral activity
In a recent study, sulfated and non-sulfated sialic acid- 
PAMAM glycodendrimers were synthesized to assess the 
anti-HIV-1 properties (Clayton et al., 2011). The diver-
gent method proved more effective than the convergent 
one in the synthesis of generation 0, 1 and 2 sialic acid-
PAMAM conjugates. The sulfo-6, a generation 2 sulfated 
sialic acid-PAMAM glycodendrimer having 16 sialic 
acids and 11 sulfate groups had the highest inhibitory 
activity in the micromolar range on all the tested HIV-1 
strains [Q23.17 (Clade A), MN.3 (Clade B), MW965.26 
(Clade C), and TV1.21 (Clade C)]. In an earlier study, 
sulfated galactosylceramide(SGalCer)-coated polypro-
pyleneimine (PPI) dendrimers showed binding affinity 
towards HIV protein, gp120, in the nanomolar (nM) range 
as compared to picomolar (pM) affinity of dextran sulfate, 
a known HIV inhibitor. These dendrimers have also pre-
vented infection in CD4-negative cells (Kensinger et al., 
2004a; 2004b). Other types of GalCer-based dendrimers 
having polyglycerol (PG) core (Morales-Serna et al., 
2010) and phosphonic acid (PA) core (Perez-Anes et al., 
2010) were studied, and shown to inhibit cell-based HIV 
assays. However, one difference between the GalCer-PG, 
GalCer-PA and GalCer-PPI based dendrimers is that the 
earlier two dendrimer types have high cytotoxic effects as 
compared to the latter, though they have binding affinities 
in the sub micromolar (μM) range (Blanzat et al., 2005; 
Perez-Anes et al., 2010). The other types of PPI core based 
dendrimers include terminating glycosphingolipid derived 
sugar head groups, 3’-siallyactose (GM3) or globotriose 
(Gb3) (Borges et al., 2010). Both these dendrimers showed 
anti-HIV-I activity in T-cells and primary peripheral blood 
mononuclear cells (PBMCs) in the sub μM range (Borges 
et al., 2010).
In another recent study, the generation one [G1]-
gallic acid-triethylene glycol (GATG) dendrimer was 
shown to inhibit the oligomerization of the HIV-1 capsid 
protein (CA) (Domenech et al., 2010). Oligomerization 
of immuature HIV-1 capsid is essential for the morpho-
genesis for its virulence and infection in the host CD4 
cells. The C-terminal domain (CTD) of the CA is involved 
in the formation of hexamers which later join to form a 
homodimer. These dendrimers have shown to dissociate 
the homodimers of CTD (Kd ~ 10 μM) similar to designed 
peptide inhibitors weakening the dimerization process 
(Garzon et al., 2004; Stitch et al., 2005; Neira, 2009). In 
another study, the second (SPL7115) and fourth generation 
(SPL7013) dendrimers comprising benzyhydryl amide 
cores and lysine branches have shown anti-HIV activity by 
blocking HIV-envelope mediated cell-to-cell fusion (Rupp 
et al., 2007; Tyssen et al., 2010). SPL7115 and SPL7013 
also inhibited the viral entry, through different mechanism 
of action, by showing high potency against CXCR4-(X4) 
and CCR5-using (R5) HIV-1 strains (Telwatte et al., 
2011). SPL7013 dendrimer, a topical microbicidal agent 
in the clinical developments, is an active pharmacological 
constituent of VivaGel®.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic 
inflammatory disorder of many tissues and organs mainly 
around the flexible joint regions. The proinflammatory 
cytokines IL-1β, IL-17 and TNF-α produced by monocytes 
(T helper cells) and macrophage colony-stimulating fac-
tor (M-CSF) produced by macrophages are involved in 
the production of mature osteoclasts (osteoclastogenesis) 
through the receptor activator of nuclear factor-κB ligand 
(RNAKL). These osteoclasts are responsible for bone 
resorption, a typical bone erosion mechanism involved 
in RA (Takayanagi, 2007). Recently, Hayder et al. (2011) 
explored the potential of dendrimers in arthritic mice 
models. They treated dendrimers capped with anionic 
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azabisphophonate (ABP) end groups, dendrimer azamo-
nophosphate (AMP) and polypropyleneimine (PPI), at a 
dose of 10 mg/kg four times weekly (figure 2A,B,C). Only 
ABP significantly inhibited the proinflammatory cytokines 
secretion and osteoclastogenesis process (Hayder et al., 
2011) (Figure 2D).
Arachidonic acid
The steroidal and non-steroidal anti-inflammatory 
drugs (NSAIDs) provide one of the main classes of anti-
inflammatory therapy that mainly inhibit the arachidonic 
acid and prostaglandin synthesis pathways. Recently, 
Tomalia and his group suggested that dendrimers them-
selves can exhibit anti-inflammatory properties mainly 
through inhibiting COX-2 activity (Chauhan et al., 2009). 
Kakkar’s group recently showed that dendrimers synthe-
sized using alkyne-azide “click” chemistry act as anti-
inflammatory agents (Castonguay et al., 2011; Hourani, 
Kakkar et al., 2010; Sharma et al., 2011a,b). Dendrimers 
with terminated acetylene (A) (DG0-A, DG1-A and DG2-
A) and hydroxyl groups (OH) (DG1-OH) (Hourani et al., 
2010) have shown to inhibit the LPS-induced nitric oxide 
(NO) and COX-2 (involved in prostaglandin (PGE2) 
synthesis in N9 microglia cells (resident immune cells of 
central nervous system). Treatment with DG1-OH showed 
the highest inhibitory activity of iNOS and COX-2 as 
compared to selective (Celecoxib) and non-selective (Ibu-
profen) anti-inflammatory agents. Further, computational 
studies showed that these dendrimers bring about the anti-
inflammatory effect by direct binding to the active site of 
the enzymes iNOS and COX-2 (Niebert et al., 2013), an 
emerging anti-inflammatory mechanism of dendrimers.
FIGURE 2 - Structure of dendrimers ABP (A), AMP (B) and PPI (C) used in IL-1ra -/- arthritis mice model studied by Hayder et al. 
(D) represent the comparative data of the effect of dendrimers ABP, AMP or PPI treated at a dose of 10 mg/kg on the development 
of external signs of arthritis (paw swelling and arthritic score) (Reprinted with permission from ACS Nano 2011, 5(9), 6779-6785. 
Copyright 2011 American Chemical Society).
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CONCLUSIONS
The unique properties of dendrimers have led to 
the development of a variety of applications of these 
macromolecules, including delivery of anti-inflammatory 
drugs. Inflammation is a complex network of events, and 
current therapies have not achieved much success in the 
treatment of inflammatory diseases as they either target a 
specific cytokine, receptor or a single cell. Recent inves-
tigations suggest that dendrimers themselves can act as 
anti-inflammatory agents. Dendrimers such as PAMAM 
terminated with carboxylic groups conjugated to glucos-
amine and related derivatives not only inhibit the release 
of cytokines but also affect the cellular phenotypes and 
functions (Shaunak et al., 2004). Azabisphophonate-based 
dendrimers showed phenotypic changes in phagocytic 
activity of human monocytes (Espinosa et al., 2001; Pou-
pot et al., 2006). Some of the dendrimers with terminal 
hydroxylted lactose end groups, such as PEO, blocked the 
binding efficacy of cell adhesion molecules (Rele et al., 
2005; Dernedde et al., 2010). While other dendrimers such 
as PPI and PAMAM with terminal sulfated galactosylce-
ramide and sialic acid groups have direct binding affinity 
with the HIV proteins, involved in HIV infections (Clayton 
et al., 2011; Kensinger et al., 2004a; 2004b) and others 
affecting the CD4 cells (Borges et al., 2010; Perez-Anes 
et al., 2010). Dendrimers such as PAMAM with terminal 
-NH2, -OH and -COOH groups have shown to inhibit 
iNOS and COX-2 (Chauhan et al., 2009). These diverse 
studies showing the anti-inflammatory properties of den-
drimers point towards the role of terminal end groups, 
overall charge and the generation number in their activity. 
Though it is too early to comment on the structure-activity 
relationships of dendrimers and their anti-inflammatory 
behavior, but it is clear that these dendrimers show great 
promise in future as potential anti-inflammatory thera-
peutic agents.
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